The role of angiotensin II in nonalcoholic steatohepatitis

Molecular and Cellular Endocrinology

Volumn 378, Issue 1-2, 2013, Pages 29-40

  Matthew Morris, E ^a,b   Fletcher, Justin A ^a,b   Thyfault, John P ^a,b   Scott Rector, R ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiotensin II; Fibrosis; Mitochondria; NAFLD; Steatosis

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOPHEROL DERIVATIVE; ANGIOTENSIN II; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIPID; MITOCHONDRIAL DNA; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TEMPOL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CELL ACTIVATION; CELL FUNCTION; CHRONIC LIVER DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DNA DAMAGE; DRUG EFFICACY; ENZYME ACTIVATION; EXPERIMENTAL MODEL; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY LIVER; HORMONE ACTION; HORMONE INHIBITION; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPID STORAGE; LIPOGENESIS; LIPOPROTEIN SECRETION; LIVER DISEASE; LIVER FIBROSIS; METABOLIC SYNDROME X; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; STEATOSIS; STELLATE CELL; TISSUE LEVEL; TREATMENT OUTCOME; UNITED STATES;

ANGIOTENSIN II; FIBROSIS; MITOCHONDRIA; NAFLD; STEATOSIS;

ANGIOTENSIN II; ANIMALS; CHRONIC DISEASE; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; METABOLIC SYNDROME X; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84884535307     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.04.013     Document Type: Review

References (164)

1. Abadir P.M., Foster D.B., Crow M., Cooke C.A., Rucker J.J., Jain A., Smith B.J., Burks T.N., Cohn R.D., Fedarko N.S., Carey R.M., O'Rourke B., Walston J.D. Identification and characterization of a functional mitochondrial angiotensin system. Proc. Natl. Acad. Sci. USA 2011, 108:14849-14854.
2. Adiels M., Olofsson S.O., Taskinen M.R., Boren J. Diabetic dyslipidaemia. Curr. Opin. Lipidol. 2006, 17:238-246.
3. Alonzi T., Maritano D., Gorgoni B., Rizzuto G., Libert C., Poli V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation (correction of activation) in the liver. Mol. Cell. Biol. 2001, 21:1621-1632.
4. Arellano-Plancarte A., Hernandez-Aranda J., Catt K.J., Olivares-Reyes J.A. Angiotensin-induced EGF receptor transactivation inhibits insulin signaling in C9 hepatic cells. Biochem. Pharmacol. 2010, 79:733-745.
5. Athyros V.G., Tziomalos K., Daskalopoulos G.N., Karagiannis A., Mikhailidis D.P. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. Ann. Med. 2011, 43:167-171.
6. Barzilay J.I., Davis B.R., Cutler J.A., Pressel S.L., Whelton P.K., Basile J., Margolis K.L., Ong S.T., Sadler L.S., Summerson J. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch. Intern. Med. 2006, 166:2191-2201.
7. Bataller R., Gines P., Nicolas J.M., Gorbig M.N., Garcia-Ramallo E., Gasull X., Bosch J., Arroyo V., Rodes J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000, 118:1149-1156.
8. Bataller R., Gabele E., Schoonhoven R., Morris T., Lehnert M., Yang L., Brenner D.A., Rippe R.A. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285:G642-G651.
9. Bataller R., Schwabe R.F., Choi Y.H., Yang L., Paik Y.H., Lindquist J., Qian T., Schoonhoven R., Hagedorn C.H., Lemasters J.J., Brenner D.A. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest. 2003, 112:1383-1394.
10. Bataller R., Gabele E., Parsons C.J., Morris T., Yang L., Schoonhoven R., Brenner D.A., Rippe R.A. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005, 41:1046-1055.
11. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology 2005, 42:44-52.
12. Begriche K., Igoudjil A., Pessayre D., Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006, 6:1-28.
13. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., Cristanini G., Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000, 132:112-117.
14. Boden G. Obesity and free fatty acids. Endocrinol. Metab. Clin. North Am. 2008, 37:635-646. viii-ix.
15. Boveris A., Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem. J. 1973, 134:707-716.
16. Bowman T.A., Ramakrishnan S.K., Kaw M., Lee S.J., Patel P.R., Golla V.K., Bourey R.E., Haram P.M., Koch L.G., Britton S.L., Wisloff U., Lee A.D., Najjar S.M. Caloric restriction reverses hepatic insulin resistance and steatosis in rats with low aerobic capacity. Endocrinology 2010, 151:5157-5164.
17. Brasier A.R. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc. Res. 2010, 86:211-218.
18. Brewster U.C., Setaro J.F., Perazella M.A. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am. J. Med. Sci. 2003, 326:15-24.
19. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., Hobbs H.H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
20. Bu D.X., Griffin G., Lichtman A.H. Mechanisms for the anti-inflammatory effects of statins. Curr. Opin. Lipidol. 2011, 22:165-170.
21. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42:987-1000.
22. Clemenz M., Frost N., Schupp M., Caron S., Foryst-Ludwig A., Bohm C., Hartge M., Gust R., Staels B., Unger T., Kintscher U. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008, 57:1405-1413.
23. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
24. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Dominguez-Diez A., Fernandez-Escalante J.C., Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001, 34:1158-1163.
25. de Cavanagh E.M., Piotrkowski B., Basso N., Stella I., Inserra F., Ferder L., Fraga C.G. Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J. 2003, 17:1096-1098.
26. de Cavanagh E.M., Flores I., Ferder M., Inserra F., Ferder L. Renin-angiotensin system inhibitors protect against age-related changes in rat liver mitochondrial DNA content and gene expression. Exp. Gerontol. 2008, 43:919-928.
27. De Minicis S., Brenner D.A. NOX in liver fibrosis. Arch. Biochem. Biophys. 2007, 462:266-272.
28. De Minicis S., Bataller R., Brenner D.A. NADPH oxidase in the liver: defensive, offensive, or fibrogenic?. Gastroenterology 2006, 131:272-275.
29. De Minicis S., Seki E., Oesterreicher C., Schnabl B., Schwabe R.F., Brenner D.A. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology 2008, 48:2016-2026.
30. Demeilliers C., Maisonneuve C., Grodet A., Mansouri A., Nguyen R., Tinel M., Letteron P., Degott C., Feldmann G., Pessayre D., Fromenty B. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology 2002, 123:1278-1290.
31. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1343-1351.
32. Doughan A.K., Harrison D.G., Dikalov S.I. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ. Res. 2008, 102:488-496.
33. Dufour J.F. NASH and thiazolidinediones: not to be taken lightly. J. Hepatol. 2007, 47:451-453.
34. Eaton S. Control of mitochondrial beta-oxidation flux. Prog. Lipid Res. 2002, 41:197-239.
35. Elks C.M., Francis J. Central adiposity, systemic inflammation, and the metabolic syndrome. Curr. Hypertens. Rep. 2010, 12:99-104.
36. Falck-Ytter Y., Younossi Z.M., Marchesini G., McCullough A.J. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 2001, 21:17-26.
37. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112.
38. Feldstein A.E., Werneburg N.W., Canbay A., Guicciardi M.E., Bronk S.F., Rydzewski R., Burgart L.J., Gores G.J. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004, 40:185-194.
39. Ferder L., Inserra F., Romano L., Ercole L., Pszenny V. Effects of angiotensin-converting enzyme inhibition on mitochondrial number in the aging mouse. Am. J. Physiol. 1993, 265:C15-C18.
40. Ferrante A.W. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J. Intern. Med. 2007, 262:408-414.
41. Finckenberg P., Eriksson O., Baumann M., Merasto S., Lalowski M.M., Levijoki J., Haasio K., Kyto V., Muller D.N., Luft F.C., Oresic M., Mervaala E. Caloric restriction ameliorates angiotensin II-induced mitochondrial remodeling and cardiac hypertrophy. Hypertension 2012, 59:76-84.
42. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
43. Flowers M.T., Miyazaki M., Liu X., Ntambi J.M. Probing the role of stearoyl-CoA desaturase-1 in hepatic insulin resistance. J. Clin. Invest. 2006, 116:1478-1481.
44. Fogari R., Maffioli P., Mugellini A., Zoppi A., Lazzari P., Derosa G. Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol. 2012, 24:164-171.
45. Gao D., Wei C., Chen L., Huang J., Yang S., Diehl A.M. Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G1070-G1077.
46. Gao D., Nong S., Huang X., Lu Y., Zhao H., Lin Y., Man Y., Wang S., Yang J., Li J. The effects of palmitate on hepatic insulin resistance are mediated by NADPH Oxidase 3-derived reactive oxygen species through JNK and p38MAPK pathways. J. Biol. Chem. 2010, 285:29965-29973.
47. Garrido A.M., Griendling K.K. NADPH oxidases and angiotensin II receptor signaling. Mol. Cell. Endocrinol. 2009, 302:148-158.
48. Georgescu E.F. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?. Adv. Ther. 2008, 25:1141-1174.
49. Georgescu E.F., Ionescu R., Niculescu M., Mogoanta L., Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 2009, 15:942-954.
50. Greco D., Kotronen A., Westerbacka J., Puig O., Arkkila P., Kiviluoto T., Laitinen S., Kolak M., Fisher R.M., Hamsten A., Auvinen P., Yki-Jarvinen H. Gene expression in human NAFLD. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G1281-G1287.
51. Griendling K.K., Ushio-Fukai M., Lassegue B., Alexander R.W. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 1997, 29:366-373.
52. Gutierrez-Juarez R., Pocai A., Mulas C., Ono H., Bhanot S., Monia B.P., Rossetti L. Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J. Clin. Invest. 2006, 116:1686-1695.
53. Haque M., Sanyal A.J. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract. Res. Clin. Gastroenterol. 2002, 16:709-731.
54. Harford K.A., Reynolds C.M., McGillicuddy F.C., Roche H.M. Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc. Nutr. Soc. 2011, 70:408-417.
55. Haukeland J.W., Damas J.K., Konopski Z., Loberg E.M., Haaland T., Goverud I., Torjesen P.A., Birkeland K., Bjoro K., Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 2006, 44:1167-1174.
56. Hedayati S.S., Elsayed E.F., Reilly R.F. Non-pharmacological aspects of blood pressure management: what are the data?. Kidney Int. 2011, 79:1061-1070.
57. Henriksen E.J. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R974-R980.
58. Henriksen E.J., Jacob S., Kinnick T.R., Teachey M.K., Krekler M. Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001, 38:884-890.
59. Hirose A., Ono M., Saibara T., Nozaki Y., Masuda K., Yoshioka A., Takahashi M., Akisawa N., Iwasaki S., Oben J.A., Onishi S. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007, 45:1375-1381.
60. Hsiao T.J., Chen J.C., Wang J.D. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int. J. Obes. Relat. Metab. Disord. 2004, 28:167-172.
61. Hsueh W.A., Wyne K. Renin-angiotensin-aldosterone system in diabetes and hypertension. J. Clin. Hypertens. (Greenwich) 2011, 13:224-237.
62. Huang M.A., Greenson J.K., Chao C., Anderson L., Peterman D., Jacobson J., Emick D., Lok A.S., Conjeevaram H.S. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am. J. Gastroenterol. 2005, 100:1072-1081.
63. Hui J.M., Kench J.G., Chitturi S., Sud A., Farrell G.C., Byth K., Hall P., Khan M., George J. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003, 38:420-427.
64. Hunyady L., Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol. Endocrinol. 2006, 20:953-970.
65. Ibdah J.A., Perlegas P., Zhao Y., Angdisen J., Borgerink H., Shadoan M.K., Wagner J.D., Matern D., Rinaldo P., Cline J.M. Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 2005, 128:1381-1390.
66. Ishizaka N., Hongo M., Sakamoto A., Saito K., Furuta K., Koike K. Liver lipid content is reduced in rat given 7-day administration of angiotensin II. J. Renin. Angiotensin Aldosterone Syst. 2011, 12:462-468.
67. Jamaluddin M., Meng T., Sun J., Boldogh I., Han Y., Brasier A.R. Angiotensin II induces nuclear factor (NF)-kappaB1 isoforms to bind the angiotensinogen gene acute-phase response element: a stimulus-specific pathway for NF-kappaB activation. Mol. Endocrinol. 2000, 14:99-113.
68. Jayasooriya A.P., Mathai M.L., Walker L.L., Begg D.P., Denton D.A., Cameron-Smith D., Egan G.F., McKinley M.J., Rodger P.D., Sinclair A.J., Wark J.D., Weisinger H.S., Jois M., Weisinger R.S. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc. Natl. Acad. Sci. USA 2008, 105:6531-6536.
69. Jones B.H., Standridge M.K., Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997, 138:1512-1519.
70. Jornayvaz F.R., Birkenfeld A.L., Jurczak M.J., Kanda S., Guigni B.A., Jiang D.C., Zhang D., Lee H.Y., Samuel V.T., Shulman G.I. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc. Natl. Acad. Sci. USA 2011, 108:5748-5752.
71. Kanno K., Tazuma S., Nishioka T., Hyogo H., Chayama K. Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. Dig. Dis. Sci. 2005, 50:942-948.
72. Kato S., Luyckx V.A., Ots M., Lee K.W., Ziai F., Troy J.L., Brenner B.M., MacKenzie H.S. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int. 1999, 56:1037-1048.
73. Kimura S., Zhang G.X., Nishiyama A., Shokoji T., Yao L., Fan Y.Y., Rahman M., Abe Y. Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide. Hypertension 2005, 45:438-444.
74. Kitamura K., Tada S., Nakamoto N., Toda K., Horikawa H., Kurita S., Tsunematsu S., Kumagai N., Ishii H., Saito H., Hibi T. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis. J. Gastroenterol. Hepatol. 2007, 22:2022-2033.
75. Kouyama R., Suganami T., Nishida J., Tanaka M., Toyoda T., Kiso M., Chiwata T., Miyamoto Y., Yoshimasa Y., Fukamizu A., Horiuchi M., Hirata Y., Ogawa Y. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005, 146:3481-3489.
76. Kudo H., Yata Y., Takahara T., Kawai K., Nakayama Y., Kanayama M., Oya T., Morita S., Sasahara M., Mann D.A., Sugiyama T. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int. 2009, 29:988-996.
77. Kurikawa N., Suga M., Kuroda S., Yamada K., Ishikawa H. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br. J. Pharmacol. 2003, 139:1085-1094.
78. Kurita S., Takamura T., Ota T., Matsuzawa-Nagata N., Kita Y., Uno M., Nabemoto S., Ishikura K., Misu H., Ando H., Zen Y., Nakanuma Y., Kaneko S. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. Eur. J. Pharmacol. 2008, 588:316-324.
79. Lardizabal J.A., Deedwania P.C. The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus. Curr. Cardiol. Rep. 2010, 12:464-471.
80. Lastra-Lastra G., Sowers J.R., Restrepo-Erazo K., Manrique-Acevedo C., Lastra-Gonzalez G. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin. Endocrinol. (Oxf.) 2009, 71:1-6.
81. Leclercq I.A., Da Silva Morais A., Schroyen B., Van Hul N., Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J. Hepatol. 2007, 47:142-156.
82. Lee K.S., Buck M., Houglum K., Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J. Clin. Invest. 1995, 96:2461-2468.
83. Lemoine M., Ratziu V., Kim M., Maachi M., Wendum D., Paye F., Bastard J.P., Poupon R., Housset C., Capeau J., Serfaty L. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 2009, 29:1431-1438.
84. Li X., Meng Y., Wu P., Zhang Z., Yang X. Angiotensin II and aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. Regul. Pept. 2007, 138:15-25.
85. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., Snapinn S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
86. Lindholm L.H., Ibsen H., Borch-Johnsen K., Olsen M.H., Wachtell K., Dahlof B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristianson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J.M., Snapinn S. Risk of new-onset diabetes in the Losartan intervention for endpoint reduction in hypertension study. J. Hypertens. 2002, 20:1879-1886.
87. Liu J.L., Irvine S., Reid I.A., Patel K.P., Zucker I.H. Chronic exercise reduces sympathetic nerve activity in rabbits with pacing-induced heart failure: a role for angiotensin II. Circulation 2000, 102:1854-1862.
88. Loguercio C., Federico A., Trappoliere M., Tuccillo C., de Sio I., Di Leva A., Niosi M., D'Auria M.V., Capasso R., Del Vecchio Blanco C. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig. Dis. Sci. 2007, 52:2387-2395.
89. Lubel J.S., Herath C.B., Burrell L.M., Angus P.W. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications. J. Gastroenterol. Hepatol. 2008, 23:1327-1338.
90. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980, 55:434-438.
91. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., Furuyama N., Kondo H., Takahashi M., Arita Y., Komuro R., Ouchi N., Kihara S., Tochino Y., Okutomi K., Horie M., Takeda S., Aoyama T., Funahashi T., Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002, 8:731-737.
92. Marchesi C., Paradis P., Schiffrin E.L. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol. Sci. 2008, 29:367-374.
93. Matsunami T., Sato Y., Ariga S., Sato T., Shimomura T., Kashimura H., Hasegawa Y., Yukawa M. Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model. Metabolism 2011, 60:805-814.
94. McGarry J.D., Leatherman G.F., Foster D.W. Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J. Biol. Chem. 1978, 253:4128-4136.
95. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 2007, 292:C82-C97.
96. Minehira K., Young S.G., Villanueva C.J., Yetukuri L., Oresic M., Hellerstein M.K., Farese R.V., Horton J.D., Preitner F., Thorens B., Tappy L. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J. Lipid Res. 2008, 49:2038-2044.
97. Miwa S., Brand M.D. Mitochondrial matrix reactive oxygen species production is very sensitive to mild uncoupling. Biochem. Soc. Trans. 2003, 31:1300-1301.
98. Miyazaki M., Flowers M.T., Sampath H., Chu K., Otzelberger C., Liu X., Ntambi J.M. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab. 2007, 6:484-496.
99. Moreno M., Ramalho L.N., Sancho-Bru P., Ruiz-Ortega M., Ramalho F., Abraldes J.G., Colmenero J., Dominguez M., Egido J., Arroyo V., Gines P., Bataller R. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G147-G156.
100. Morris E.M., Rector R.S., Thyfault J.P., Ibdah J.A. Mitochondria and redox signaling in steatohepatitis. Antioxid. Redox Signal. 2011, 15:485-504.
101. Motley E.D., Eguchi K., Gardner C., Hicks A.L., Reynolds C.M., Frank G.D., Mifune M., Ohba M., Eguchi S. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha. Hypertension 2003, 41:775-780.
102. Munshi M.K., Uddin M.N., Glaser S.S. The role of the renin-angiotensin system in liver fibrosis. Exp. Biol. Med. (Maywood) 2011, 236:557-566.
103. Nabeshima Y., Tazuma S., Kanno K., Hyogo H., Chayama K. Deletion of angiotensin II type I receptor reduces hepatic steatosis. J. Hepatol. 2009, 50:1226-1235.
104. Neuschwander-Tetri B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010, 52:774-788.
105. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003, 37:1202-1219.
106. Nilssen L.S., Dajani O., Christoffersen T., Sandnes D. Sustained diacylglycerol accumulation resulting from prolonged G protein-coupled receptor agonist-induced phosphoinositide breakdown in hepatocytes. J. Cell. Biochem. 2005, 94:389-402.
107. Nobili V., Pinzani M. Paediatric non-alcoholic fatty liver disease. Gut 2010, 59:561-564.
108. Nohl H., Gille L., Staniek K. Intracellular generation of reactive oxygen species by mitochondria. Biochem. Pharmacol. 2005, 69:719-723.
109. Ogden C.L., Carroll M.D., Curtin L.R., Lamb M.M., Flegal K.M. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010, 303:242-249.
110. Ogihara T., Asano T., Ando K., Chiba Y., Sakoda H., Anai M., Shojima N., Ono H., Onishi Y., Fujishiro M., Katagiri H., Fukushima Y., Kikuchi M., Noguchi N., Aburatani H., Komuro I., Fujita T. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002, 40:872-879.
111. Oh S.Y., Cho Y.K., Kang M.S., Yoo T.W., Park J.H., Kim H.J., Park D.I., Sohn C.I., Jeon W.K., Kim B.I., Son B.H., Shin J.H. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 2006, 55:1604-1609.
112. Olivares-Reyes J.A., Arellano-Plancarte A., Castillo-Hernandez J.R. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol. Cell. Endocrinol. 2009, 302:128-139.
113. Oza N., Eguchi Y., Mizuta T., Ishibashi E., Kitajima Y., Horie H., Ushirogawa M., Tsuzura T., Nakashita S., Takahashi H., Kawaguchi Y., Oda Y., Iwakiri R., Ozaki I., Eguchi T., Ono N., Fujimoto K. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J. Gastroenterol. 2009, 44:1203-1208.
114. Paik Y.H., Iwaisako K., Seki E., Inokuchi S., Schnabl B., Osterreicher C.H., Kisseleva T., Brenner D.A. The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology 2011, 53:1730-1741.
115. Pellieux C., Aasum E., Larsen T.S., Montessuit C., Papageorgiou I., Pedrazzini T., Lerch R. Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway. J. Mol. Cell. Cardiol. 2006, 41:459-466.
116. Pellieux C., Montessuit C., Papageorgiou I., Lerch R. Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-alpha. Cardiovasc. Res. 2009, 82:341-350.
117. Pereira R.M., dos Santos R.A., da Costa Dias F.L., Teixeira M.M., Simoes e Silva A.C. Renin-angiotensin system in the pathogenesis of liver fibrosis. World J. Gastroenterol. 2009, 15:2579-2586.
118. Perez-Carreras M., Del Hoyo P., Martin M.A., Rubio J.C., Martin A., Castellano G., Colina F., Arenas J., Solis-Herruzo J.A. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003, 38:999-1007.
119. Pessayre D., Fromenty B. NASH: a mitochondrial disease. J. Hepatol. 2005, 42:928-940.
120. Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., Fava J.L., Wing R.R. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
121. Ran J., Hirano T., Adachi M. Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E955-E961.
122. Ran J., Hirano T., Adachi M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E227-E232.
123. Ran J., Hirano T., Adachi M. Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. J. Hypertens. 2005, 23:1525-1530.
124. Rector R.S., Thyfault J.P., Wei Y., Ibdah J.A. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J. Gastroenterol. 2008, 14:185-192.
125. Rector R.S., Thyfault J.P., Morris R.T., Laye M.J., Borengasser S.J., Booth F.W., Ibdah J.A. Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in otsuka long-evans tokushima fatty rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G619-G626.
126. Rector R.S., Thyfault J.P., Uptergrove G.M., Morris E.M., Naples S.P., Borengasser S.J., Mikus C.R., Laye M.J., Laughlin M.H., Booth F.W., Ibdah J.A. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J. Hepatol. 2010, 52:727-736.
127. Rector R.S., Uptergrove G.M., Morris E.M., Borengasser S.J., Laughlin M.H., Booth F.W., Thyfault J.P., Ibdah J.A. Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 300:G874-G883.
128. Reinehr R., Becker S., Keitel V., Eberle A., Grether-Beck S., Haussinger D. Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 2005, 129:2009-2031.
129. Rong X., Li Y., Ebihara K., Zhao M., Kusakabe T., Tomita T., Murray M., Nakao K. Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia. Br. J. Pharmacol. 2010, 160:1796-1807.
130. Ruiz-Ortega M., Bustos C., Hernandez-Presa M.A., Lorenzo O., Plaza J.J., Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J. Immunol. 1998, 161:430-439.
131. Ruiz-Ortega M., Lorenzo O., Ruperez M., Blanco J., Egido J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am. J. Pathol. 2001, 158:1743-1756.
132. Schindhelm R.K., Diamant M., Dekker J.M., Tushuizen M.E., Teerlink T., Heine R.J. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab. Res. Rev. 2006, 22:437-443.
133. Schwimmer J.B., Deutsch R., Kahen T., Lavine J.E., Stanley C., Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006, 118:1388-1393.
134. Shetty S., Ramos-Roman M.A., Cho Y.R., Brown J., Plutzky J., Muise E.S., Horton J.D., Scherer P.E., Parks E.J. Enhanced fatty acid flux triggered by adiponectin overexpression. Endocrinology 2012, 153:113-122.
135. Sorescu D., Griendling K.K. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest. Heart Fail. 2002, 8:132-140.
136. Sugimoto K., Qi N.R., Kazdova L., Pravenec M., Ogihara T., Kurtz T.W. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006, 47:1003-1009.
137. Sugimoto K., Kazdova L., Qi N.R., Hyakukoku M., Kren V., Simakova M., Zidek V., Kurtz T.W., Pravenec M. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. J. Hypertens. 2008, 26:1209-1215.
138. Szostak J., Laurant P. The forgotten face of regular physical exercise: a 'natural' anti-atherogenic activity. Clin. Sci. (Lond.) 2011, 121:91-106.
139. Takahashi N., Li F., Hua K., Deng J., Wang C.H., Bowers R.R., Bartness T.J., Kim H.S., Harp J.B. Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab. 2007, 6:506-512.
140. Takeshita Y., Takamura T., Ando H., Hamaguchi E., Takazakura A., Matsuzawa-Nagata N., Kaneko S. Cross talk of tumor necrosis factor-alpha and the renin-angiotensin system in tumor necrosis factor-alpha-induced plasminogen activator inhibitor-1 production from hepatocytes. Eur. J. Pharmacol. 2008, 579:426-432.
141. Thoma C., Day C.P., Trenell M.I. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J. Hepatol. 2012, 56:255-266.
142. Thyfault J.P., Rector R.S., Uptergrove G.M., Borengasser S.J., Morris E.M., Wei Y., Laye M.J., Burant C.F., Qi N.R., Ridenhour S.E., Koch L.G., Britton S.L., Ibdah J.A. Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury. J. Physiol. 2009, 587:1805-1816.
143. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 2000, 343:1467-1476.
144. Toblli J.E., Munoz M.C., Cao G., Mella J., Pereyra L., Mastai R. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring) 2008, 16:770-776.
145. Tomas E., Tsao T.S., Saha A.K., Murrey H.E., Zhang Cc C., Itani S.I., Lodish H.F., Ruderman N.B. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl. Acad. Sci. USA 2002, 99:16309-16313.
146. Tsochatzis E.A., Papatheodoridis G.V., Archimandritis A.J. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm. 2009, 2009:831670.
147. Wei Y., Sowers J.R., Nistala R., Gong H., Uptergrove G.M., Clark S.E., Morris E.M., Szary N., Manrique C., Stump C.S. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J. Biol. Chem. 2006, 281:35137-35146.
148. Wei Y., Clark S.E., Morris E.M., Thyfault J.P., Uptergrove G.M., Whaley-Connell A.T., Ferrario C.M., Sowers J.R., Ibdah J.A. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J. Hepatol. 2008, 49:417-428.
149. Wei Y., Sowers J.R., Clark S.E., Li W., Ferrario C.M., Stump C.S. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E345-E351.
150. Wei Y., Chen K., Whaley-Connell A.T., Stump C.S., Ibdah J.A., Sowers J.R. Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 294:R673-R680.
151. Wei Y., Clark S.E., Thyfault J.P., Uptergrove G.M., Li W., Whaley-Connell A.T., Ferrario C.M., Sowers J.R., Ibdah J.A. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am. J. Pathol. 2009, 174:1329-1337.
152. Wieckowska A., Papouchado B.G., Li Z., Lopez R., Zein N.N., Feldstein A.E. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2008, 103:1372-1379.
153. Wilson P.W., D'Agostino R.B., Parise H., Sullivan L., Meigs J.B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066-3072.
154. Wobser H., Dorn C., Weiss T.S., Amann T., Bollheimer C., Buttner R., Scholmerich J., Hellerbrand C. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 2009, 19:996-1005.
155. Yadav A., Saini V., Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin. Chim. Acta 2010, 411:1570-1579.
156. Yamamoto E., Dong Y.F., Kataoka K., Yamashita T., Tokutomi Y., Matsuba S., Ichijo H., Ogawa H., Kim-Mitsuyama S. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension 2008, 52:573-580.
157. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002, 8:1288-1295.
158. Yew N.S., Zhao H., Hong E.G., Wu I.H., Przybylska M., Siegel C., Shayman J.A., Arbeeny C.M., Kim J.K., Jiang C., Cheng S.H. Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase. PLoS ONE 2010, 5:e11239.
159. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., Hasegawa T., Tokusashi Y., Miyokawa N., Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-1225.
160. Yokozawa J., Sasaki T., Ohwada K., Sasaki Y., Ito J.I., Saito T., Kawata S. Down-regulation of hepatic stearoyl-CoA desaturase 1 expression by angiotensin II receptor blocker in the obese fa/fa Zucker rat: possible role in amelioration of insulin resistance and hepatic steatosis. J. Gastroenterol. 2009, 44:583-591.
161. Younossi Z.M., Diehl A.M., Ong J.P. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002, 35:746-752.
162. Yusuf S., Ostergren J.B., Gerstein H.C., Pfeffer M.A., Swedberg K., Granger C.B., Olofsson B., Probstfield J., McMurray J.V. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005, 112:48-53.
163. Yvan-Charvet L., Quignard-Boulange A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int. 2011, 79:162-168.
164. Yvan-Charvet L., Even P., Bloch-Faure M., Guerre-Millo M., Moustaid-Moussa N., Ferre P., Quignard-Boulange A. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 2005, 54:991-999.